SuperworthANI Pharmaceuticals market cap ANIP
Share price times shares outstanding: what the whole company sells for, since 2011.
- Today, Oct 23, 2026
- $1.7B
- Highest close in our data
- $2.1B
- Sep 2025
ANI Pharmaceuticals is worth $1.7B at the close on Oct 23, 2026, at $72.61 a share.
That is down 18% over the last year and up 250% over five years.
Its highest close in our data was $2.1B in Sep 2025.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $1.7B | $1.6B | $2B | −10% |
| 2025 | $1.9B | $1.2B | $2.1B | +62% |
| 2024 | $1.1B | $1.1B | $1.5B | +2% |
| 2023 | $1.1B | $658.3M | $1.3B | +60% |
| 2022 | $702.6M | $420.5M | $727.6M | +20% |
| 2021 | $587.6M | $350.2M | $649.1M | +64% |
| 2020 | $358.9M | $292.8M | $793.9M | −52% |
| 2019 | $741.5M | $578.9M | $1B | +43% |
| 2018 | $520.2M | $488.2M | $842.6M | −31% |
| 2017 | $751.1M | $510.9M | $868.9M | +7% |
| 2016 | $702.7M | $333.6M | $801.9M | +35% |
| 2015 | $518.9M | $474.2M | $811.5M | −16% |
| 2014 | $617.9M | $178.7M | $623.7M | +227% |
| 2013 | $188.8M | $23.3M | $188.8M | +517% |
| 2012 | $30.6M | $27.4M | $93.5M | −44% |
| 2011 | $55M | $49.5M | $302.5M | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest ANI Pharmaceuticals' size, closest first, today.
| Company | Market cap |
|---|---|
| ANIPANI Pharmaceuticals | $1.7B |
| PAHCPhibro Animal Health | $1.6B |
| ANABAnaptysbio | $1.5B |
| PCRXPacira BioSciences | $1.5B |
| HRMYHarmony Biosciences | $2.1B |
| PBHPrestige Consumer Healthcare | $2.3B |
| OMEROmeros | $1.2B |
| AMPHAmphastar Pharmaceuticals | $1.1B |
| NRIXNurix Therapeutics | $2.8B |
| ABUSArbutus Biopharma | $831M |
| OGNOrganon | $3.6B |
| Peer median | $1.5B |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on ANI Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.